Catabasis Pharmaceuticals, Inc. (CATB) Stock Price Up -3.1%
Shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) rose 3.1% during trading on Friday . The company traded as high as $2.25 and last traded at $2.16. Approximately 1,286,381 shares changed hands during mid-day trading, an increase of 8% from the average daily volume of 1,188,200 shares. The stock had previously closed at $2.23.
CATB has been the subject of a number of recent research reports. Oppenheimer Holdings, Inc. cut their price objective on shares of Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a report on Tuesday, August 15th. Citigroup Inc. reiterated a “hold” rating and issued a $1.50 price objective on shares of Catabasis Pharmaceuticals in a report on Friday. HC Wainwright increased their price objective on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Catabasis Pharmaceuticals in a report on Wednesday, June 21st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $4.00.
The stock’s market capitalization is $47.66 million. The firm’s 50 day moving average is $1.57 and its 200-day moving average is $1.57.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08. Equities analysts forecast that Catabasis Pharmaceuticals, Inc. will post ($1.39) earnings per share for the current year.
Several large investors have recently bought and sold shares of the company. Virtu KCG Holdings LLC acquired a new position in shares of Catabasis Pharmaceuticals in the second quarter valued at approximately $271,000. Oppenheimer & Co. Inc. raised its position in shares of Catabasis Pharmaceuticals by 33.3% in the second quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 30,000 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Catabasis Pharmaceuticals in the first quarter valued at approximately $106,000. 32.90% of the stock is owned by institutional investors and hedge funds.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.